Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Guess HA: Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992, 14:131–153.
2. Boyle P, Liu GF, Jacobsen S, et al.: Committee 1: Epidemiology and natural history. In Benign Prostatic Hyperplasia, edn 5. Edited by Chatelain C, Denis L, Foo KT, et al. United Kingdom: Health Publication Ltd.; 2001:17–68.
3. Neuhouser ML, Kristal AR, Penson DF: Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology 2004, 64:201–211.
4. Roberts RO, Lieber MM, Jacobson DJ, et al.: Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 2005, 80:759–764.
5. Mochtar CA, Kiemeney LA, Laguna MP, et al.: Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005, 65:300–305.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献